Abstract:The Notch signaling pathway has been identified as a therapeutic target for cancers. γ-Secretase inhibitors (GSIs) have been progressively recognized as potential anticancer drugs. The present study aimed to investigate the effects of anti-delta like legend 4 (anti-DLL4) treatment on the anticancer efficacy of GSIs in gastric cancer. SGC-7901-GFP human gastric cancer cells were tested for DLL4 expression by rosette formation test and immunofluorescence, and then were treated with anti-DLL4 antibody N-[N-(3,5-difluorophenacetyl)-L-ananyl]-S-phenylglycine t-butyl ester (DAPT, a type of GSI), or a combination of anti-DLL4 antibody and DAPT. The effects of in vitro treatments on cell apoptosis, cell cycle, and cell invasion were analyzed. For in vivo study, an orthotopic mouse model of gastric cancer was established with green fluorescence expressing SGC-7901. Ultrasound targeted microbubble destruction was used to treat tumor-bearing mice with anti-DLL4 antibody conjugated microbubbles, DAPT, and a combination of the two. Real-time fluorescence imaging was performed to assess tumor cell inhibition in each group. Following in vivo treatments, apoptosis of tumor cells and the expression of apoptosis-related genes BAX, Bcl-2, and P53 were detected by TUNEL and immunohistochemical staining. In vivo combined treatment of anti-DLL4 and DAPT led to a higher rate of cell apoptosis and greater inhibition of cell invasion than that observed with DAPT treatment alone. DAPT and anti-DLL4 combination therapy resulted in decreased cell distribution at G1 phase and increased cell distribution at S phase, compared to the untreated control group (P < .01). In vivo combined therapy with anti-DLL4 and DAPT significantly increased tumor growth inhibition and tumor cell apoptosis when compared to DAPT therapy alone (P < .05). In addition, combined treatment significantly increased expression of BAX and P53 and reduced Bcl-2 expression (P < .05). Conversely, treatment with DAPT alone only increased expression of BAX and P53 (P < .05), suggesting that the reduction of Bcl-2 expression may play an important role in the synergetic antitumor and proapoptosis effects of the combined treatment. Concurrent treatment with anti-DLL4 enhances the antitumor and proapoptotic efficacy of the γ-secretase inhibitor in gastric cancer both in vitro and in vivo.

Synergistic Anti-tumor Αctivity of Sunitinib Combined with Combretastatin A-4 in SGC-7901 Cells by Apoptosis

Concurrent Treatment with Anti-DLL4 Enhances Antitumor and Proapoptotic Efficacy of a Γ-Secretase Inhibitor in Gastric Cancer.

Synergistic antitumor effect of TRAIL in combination with sunitinib in vitro and in vivo.

Anti-proliferative and Apoptotic Effects of S1, a Tetrandrine Derivative, in Human Gastric Cancer BGC-823 Cells

Enhanced Proliferation Inhibition and Apoptosis in Glioma Cells Elicited by Combination of Irinotecan and Imatinib

[Anticancer Effect of SN-38 Combined with Sorafenib on Hepatocellular Carcinoma in Vitro and Its Mechanism].

Autophagy blockade sensitizes the anticancer activity of CA-4 via JNK-Bcl-2 pathway.

Novel Combretastatin A-4 Derivative XN0502 Induces Cell Cycle Arrest and Apoptosis in A549 Cells.

The Anti-Angiogenic Effect and Novel Mechanisms of Action of Combretastatin A-4

Synthesis and Biological Evaluation of Combretastatin A-4 Derivatives Containing a 3'-O-substituted Carbonic Ether Moiety As Potential Antitumor Agents.

Enhanced Anti-Tumor Activity by the Combination of TRAIL/Apo-2L and Combretastatin A-4 Against Human Colon Cancer Cells Via Induction of Apoptosis in Vitro and in Vivo.

Sunitinib (SUTENT, SU11248) Suppresses Tumor Growth and Induces Apoptosis in Xenograft Models of Human Hepatocellular Carcinoma.

Synergistic Inhibition of Sunitinib and Ethaselen Against Human Colorectal Cancer Cells Proliferation.

Data from Synergistic Antitumor Activity of Gemcitabine and ABT-737 <i>In Vitro and In Vivo</i> through Disrupting the Interaction of USP9X and Mcl-1

Preclinical Development Synergistic Antitumor Activity of Gemcitabine and ABT-737 In Vitro and In Vivo through Disrupting the Interaction of USP 9 X and Mcl-1

Antineoplastic effects of Endostar combined with combretastatin A4 phosphate in vitro

Inhibition of EZH2 and EGFR produces a synergistic effect on cell apoptosis by increasing autophagy in gastric cancer cells.

Combining Combretastatin A4 Phosphate with Ginsenoside Rd Synergistically Inhibited Hepatocellular Carcinoma by Reducing HIF-1α Via PI3K/AKT/mTOR Signalling Pathway.

The Green Tea Polyphenol EGCG Potentiates the Antiproliferative Activity of Sunitinib in Human Cancer Cells

Dihydroberberine Exhibits Synergistic Effects with Sunitinib on NSCLC NCI‐H460 Cells by Repressing MAP Kinase Pathways and Inflammatory Mediators

Effect of Sunitinib Combined with Ionizing Radiation on Endothelial Cells